Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21740-21754

  Kharaziha, Pedram ^a   Chioureas, Dimitris ^a   Rutishauser, Dorothea ^a,b   Baltatzis, George ^c   Lennartsson, Lena ^a   Fonseca, Pedro ^a   Azimi, Alireza ^a   Hultenby, Kjell ^d   Zubarev, Roman ^a,b   Ullén, Anders ^a   Yachnin, Jeffrey ^a   Nilsson, Sten ^a   Panaretakis, Theocharis ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarkers; Docetaxel; Exosomes; Prostate cancer; Resistance

Indexed keywords

BINDING PROTEIN; DOCETAXEL; ENDOPHILIN; ENDOPHILIN A2; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; PROTEIN PABP4; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CABAZITAXEL; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PABPC4 PROTEIN, HUMAN; PLASMA PROTEIN; POLYADENYLIC ACID BINDING PROTEIN; PROTEOME; SH3GL1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TAXOID; TUMOR MARKER;

ADULT; AGED; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRADATION; DRUG RESPONSE; DRUG SENSITIVITY; EXOSOME; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); WESTERN BLOTTING; BIOLOGY; CELL DEATH; CHEMISTRY; COHORT ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PROSTATE TUMOR; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOOD PROTEINS; CELL DEATH; CELL LINE, TUMOR; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; EXOSOMES; EXTRACELLULAR MATRIX; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NANOPARTICLES; P-GLYCOPROTEINS; POLY(A)-BINDING PROTEINS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEOME; TAXOIDS;

EID: 84940467558     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3226     Document Type: Article

References (39)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004; 351:1502-1512.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:242-245.
3. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nature reviews Cancer. 2010; 10:194-204.
4. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nature reviews Clinical oncology. 2011; 8:12-23.
5. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond, PSA: the next generation of prostate cancer biomarkers. Science translational medicine. 2012; 4:127rv123.
6. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature reviews Cancer. 2008; 8:268-278.
7. Gercel-Taylor C, Atay S, Tullis RH, Kesimer M, Taylor DD. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Analytical biochemistry. 2012; 428:44-53.
8. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic oncology. 2008; 110:13-21.
9. Drake RR, Kislinger T. The proteomics of prostate cancer exosomes. Expert review of proteomics. 2014; 11:167-177.
10. Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den Berg MS, Willemsen R, Luider T, Pasa-Tolic L, Jenster G. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PloS one. 2013; 8:e82589.
11. Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA. Prostate cancer biomarker profiles in urinary sediments and exosomes. The Journal of urology. 2014; 191:1132-1138.
12. Llorente A, Skotland T, Sylvanne T, Kauhanen D, Rog T, Orlowski A, Vattulainen I, Ekroos K, Sandvig K. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochimica et biophysica acta. 2013; 1831:1302-1309.
13. Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, Qureshi T, Al-Nedawi K. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PloS one. 2013; 8:e70047.
14. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochimica et biophysica acta. 2012; 1819:1154-1163.
15. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. European urology. 2011; 59:823-831.
16. Tian T, Zhu YL, Hu FH, Wang YY, Huang NP, Xiao ZD. Dynamics of exosome internalization and trafficking. Journal of cellular physiology. 2013; 228:1487-1495.
17. Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. Journal of cellular biochemistry. 2010; 111:488-496.
18. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999; 94:3791-3799.
19. Bobrie A, Colombo M, Krumeich S, Raposo G, Thery C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. Journal of extracellular vesicles. 2012; 1;18397.
20. Penninger JM, Kroemer G. Mitochondria, AIF and caspases-rivaling for cell death execution. Nature cell biology. 2003; 5:97-99.
21. Kjaerulff O, Brodin L, Jung A. The structure and function of endophilin proteins. Cell biochemistry and biophysics. 2011; 60:137-154.
22. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O'Driscoll L. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PloS one. 2012; 7:e50999.
23. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996; 87:507-517.
24. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. Journal of cellular physiology. 2012; 227:658-667.
25. Derry MC, Yanagiya A, Martineau Y, Sonenberg N. Regulation of poly(A)-binding protein through PABP-interacting proteins. Cold Spring Harbor symposia on quantitative biology. 2006; 71:537-543.
26. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature cell biology. 2007; 9:654-659.
27. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:3742-3748.
28. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:1481-1488.
29. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:1489-1495.
30. Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD14. PloS one. 2012; 7:e40716.
31. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate cancer and prostatic diseases. 2010; 13:6-11.
32. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer research. 1999; 59:5719-5723.
33. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. Journal of molecular medicine. 2013; 91:431-437.
34. Wang Y, McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. The Journal of cell biology. 2012; 196:375-385.
35. Steinestel K, Bruderlein S, Lennerz JK, Steinestel J, Kraft K, Propper C, Meineke V, Moller P. Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Molecular cancer. 2014; 13:145.
36. Artym VV, Yamada KM, Mueller SC. ECM degradation assays for analyzing local cell invasion. Methods in molecular biology. 2009; 522:211-219.
37. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. The Journal of clinical investigation. 2008; 118:3051-3064.
38. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current protocols in cell biology/editorial board, Juan S Bonifacino [et al]. 2006; Chapter 3:Unit 3 22.
39. Lyutvinskiy Y, Yang H, Rutishauser D, Zubarev RA. In silico instrumental response correction improves precision of label-free proteomics and accuracy of proteomics-based predictive models. Molecular & cellular proteomics: MCP. 2013; 12:2324-2331.